Post Marketing Information DHCPL 13/09/2024 Lunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis PAC 22/10/2024 Important Safety Information for Patients receiving LUNSUMIO (Mosunetuzumab): Patient Card
INTRAVENOUS Select a brand starting with the letter: L LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML [SIN17001P] LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML [SIN17002P]